公开(公告)号：US20240360239A1

公开(公告)日：2024-10-31

申请号：US18644984

申请日：2024-04-24

Applicant: Kling Biotherapeutics B.V.

Inventor： Hergen SPITS ,  Paula Maria Wilhelmina VAN HELDEN ,  Remko SCHOTTE ,  Wouter POS ,  Christien FATMAWATI ,  Danïel Michiel GO ,  Koen WAGNER ,  Julien Christian VILLAUDY

IPC: C07K16/28 ,  A61K39/00 ,  A61P35/00 ,  C07K14/705 ,  G01N33/574

CPC classification number: C07K16/2896 ,  A61P35/00 ,  C07K14/70596 ,  C07K16/2818 ,  G01N33/57492 ,  A61K2039/505 ,  A61K2039/507 ,  C07K2317/21 ,  C07K2317/34 ,  C07K2317/54 ,  C07K2317/73 ,  C07K2317/732 ,  C07K2317/734 ,  G01N2333/70596

Abstract: The present invention provides novel binding compounds and therapeutic applications thereof.

公开(公告)号：US12129299B2

公开(公告)日：2024-10-29

申请号：US16967079

申请日：2019-01-29

Applicant: ONCOC4, INC. ,  University of Maryland, Baltimore

Inventor： Yang Liu ,  Pan Zheng ,  Fei Tang ,  Mingyue Liu ,  Martin Devenport ,  Xuexiang Du ,  Yan Zhang

IPC: C07K16/28

CPC classification number: C07K16/2818 ,  C07K16/2827 ,  C07K2317/565 ,  C07K2317/71

Abstract: This invention relates to anti-CTLA-4 antibody compositions that bind to the human CTLA-4 molecule, and the use of the compositions in cancer immunotherapy and for reducing autoimmune side effects compared to other immunotherapeutic agents.

公开(公告)号：US20240352126A1

公开(公告)日：2024-10-24

申请号：US18688170

申请日：2022-09-02

Applicant: DR. REDDY’S LABORATORIES LIMITED

Inventor： Murali JAYARAMAN ,  Saisharan K GOUD ,  Sunil Ashok NANKAR ,  Maya NANATH ,  Lovisha AGGARWAL ,  Puja SARKAR ,  Mahesh INGALE ,  Reinhard JACOB ,  Abirami SURESH ,  R. L. Shri Ranga PRIYA ,  Suman LABALA

IPC: C07K16/28 ,  A61K9/08 ,  A61K39/00 ,  A61K47/12 ,  A61K47/18 ,  A61K47/26

CPC classification number: C07K16/2818 ,  A61K9/08 ,  A61K47/12 ,  A61K47/183 ,  A61K47/26 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/94

Abstract: The present invention relates to pharmaceutical formulations of antibodies and antigen-binding fragments against human programmed death receptor-1 (PD-1)/programmed death receptor Ligand 1 (PD-L1), and method for preparing the same. The disclosed formulations are free of chelators and stabilizes anti-PD1/anti-PD L1 antibody from lower to higher concentrations rendering it suitable for different modes of administration (subcutaneous/intravenous).

公开(公告)号：US20240350589A1

公开(公告)日：2024-10-24

申请号：US18683180

申请日：2022-08-16

Applicant: Cytune Pharma

Inventor： Lenka Kyrych Sadilkova ,  Ulrich Moebius ,  David Béchard ,  Irena Adkins

IPC: A61K38/20 ,  A61K9/00 ,  A61K38/17 ,  A61K45/06 ,  A61K47/68 ,  A61P35/00 ,  C07K16/28

CPC classification number: A61K38/2086 ,  A61K9/0019 ,  A61K38/1793 ,  A61K45/06 ,  A61K47/6855 ,  A61P35/00 ,  C07K16/2818 ,  C07K16/2827

Abstract: The invention relates to an interleukin-2/interleukin-receptor βγ(IL-2/IL-15Rβγ) agonist for use in treating cancer in a patient, wherein said IL-2/IL-15Rβγ agonist is administered in combination with a cytotoxic compound capable of inducing immunogenic cell death (TCD) or in combination with an application of a modality capable of inducing TCD.

公开(公告)号：US20240343758A1

公开(公告)日：2024-10-17

申请号：US18620649

申请日：2024-03-28

Applicant: Kashiv BioSciences, LLC

Inventor： Om Narayan ,  Tarun Kumar Gupta ,  Mayankkumar Thakkar ,  Roshan Ganeshlal Upadhyay

IPC: C07K1/16 ,  C07K16/22 ,  C07K16/28

CPC classification number: C07K1/165 ,  C07K16/22 ,  C07K16/2818 ,  C07K16/2878

Abstract: The present invention relates to purification process of pharmacologically active IgG1 containing protein comprising at least affinity chromatography followed by mixed-mode chromatography. The present invention provides cytotoxic T-lymphocyte-associated 4-immunoglobulin (CTLA4-Ig) fusion protein by using at least affinity chromatography, mixed-mode chromatography and optionally one or more suitable purification steps that provides purified composition of the fusion protein, substantially free of impurities selected from Pre-Peak, product and process related impurities. Further, the present invention provides highly purified CTLA4-Ig fusion protein with reduced heterogeneity.

公开(公告)号：US12110331B2

公开(公告)日：2024-10-08

申请号：US18491182

申请日：2023-10-20

Applicant: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA ,  VETIGENICS, INC.

Inventor： Nicola J. Mason ,  Donald L. Siegel ,  Nicholas Chester

IPC: C07K16/28

CPC classification number: C07K16/2818 ,  C07K2317/20 ,  C07K2317/622 ,  C07K2317/76 ,  C07K2317/92

Abstract: The present invention relates to canine antibodies, binding polypeptides, and scFvs specific for canine cytotoxic T lymphocyte associated protein 4 (CTLA-4).

公开(公告)号：US20240327522A1

公开(公告)日：2024-10-03

申请号：US18621505

申请日：2024-03-29

Applicant: Genentech, Inc.

Inventor： WeiYu LIN ,  Kelly Michele LOYET ,  Matthieu MASUREEL ,  Minh THAI ,  Shannon Jennifer TURLEY ,  Tulika TYAGI ,  Yan WU ,  Jianhuan ZHANG ,  Alessandra CASTIGLIONI ,  Cecilia Pui Chi CHIU

IPC: C07K16/28 ,  A61K39/00 ,  A61P35/00

CPC classification number: C07K16/2842 ,  A61P35/00 ,  C07K16/2818 ,  A61K2039/507 ,  C07K2317/24 ,  C07K2317/52 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/92

Abstract: Provided herein are anti-αvβ8 antibodies or antigen-binding portions thereof and methods of making and using the same. Further provided are methods of treating cancer with an anti-αvβ8 and a PD-1 axis antagonist.

公开(公告)号：US20240327506A1

公开(公告)日：2024-10-03

申请号：US18620778

申请日：2024-03-28

Applicant: MaineHealth

Inventor： Xianghua Han ,  Jennifer M. Caron ,  Peter C. Brooks

IPC: C07K16/18 ,  A61K35/17 ,  A61P35/00 ,  C07K16/28

CPC classification number: C07K16/18 ,  A61K35/17 ,  A61P35/00 ,  C07K16/2818 ,  C07K16/2827 ,  C07K16/2848

Abstract: The present invention provides compositions and methods of use thereof in the treatment of cancer and abnormal immune suppression diseases by enhancing adoptive cell therapy. In some embodiments, the methods provided herein increase T-cell infiltration into a tumor.

公开(公告)号：US20240325446A1

公开(公告)日：2024-10-03

申请号：US18674562

申请日：2024-05-24

Applicant: Iovance Biotherapeutics, Inc.

Inventor： Maria FARDIS ,  Friedrich Graf Finck FINCKENSTEIN ,  Zelanna GOLDBERG

IPC: A61K35/17 ,  A61K38/20 ,  A61K39/00 ,  A61P35/04 ,  C07K16/28

CPC classification number: A61K35/17 ,  A61K38/2013 ,  A61P35/04 ,  C07K16/2818 ,  A61K2039/505 ,  A61K2039/545

Abstract: The present invention provides improved and/or shortened processes and methods for preparing TILs in order to prepare therapeutic populations of TILs with increased therapeutic efficacy for the treatment of cancer with TILs in combination with CTLA-4 and PD-1 inhibitors and/or PD-L1 inhibitors as described herein.

公开(公告)号：US12102680B2

公开(公告)日：2024-10-01

申请号：US16806658

申请日：2020-05-15

Applicant: Merck Sharp & Dohme LLC

Inventor： Sybil M. G. Williams ,  Drake LaFace ,  Laurence Fayadat-Dilman ,  Gopalan Raghunathan ,  Linda Liang ,  Wolfgang Seghezzi

IPC: A61K39/395 ,  A61K45/06 ,  C07K16/28 ,  A61K39/00

CPC classification number: A61K39/39541 ,  A61K39/3955 ,  A61K45/06 ,  C07K16/28 ,  C07K16/2803 ,  C07K16/2818 ,  A61K2039/505 ,  A61K2039/507 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/34 ,  C07K2317/52 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/73 ,  C07K2317/74 ,  C07K2317/76 ,  C07K2317/92

Abstract: The present invention relates to anti-TIGIT antibodies, as well as use of these antibodies in the treatment of diseases such as cancer and infectious disease.